High Content Screening of synucleinopathy in primary cortical neurons : dissecting out the interplay between the basic synuclein pools
Objective: To set up a robust (see ref 1 for definition) 96-well High Content Screening assay of synucleinopathy in primary cultures of cortical neurons. Background:…Continuous dopaminergic treatment with levodopa/carbidopa intestinal gel in multiple system atrophy: report of three patients
Objective: To evaluate the effect of continuous dopaminergic treatment with levodopa/carbidopa intestinal gel (LCID) on motor and non-motor symptoms in multiple system atrophy (MSA) patients.…Preferred place of death (PPOD) in PD, PSP and MSA
Objective: To ascertain whether people with PD, PSP and MSA have a PPOD Background: Achieving a PPOD is felt to be an important factor in…Is safinamide helpful in multiple system atrophy?
Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation
Objective: To evaluate the safety, tolerability and pharmacokinetics of PBT434 in healthy volunteers. Background: PBT434 is a novel, small molecule inhibitor of alpha-synuclein aggregation. In…Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial
Objective: Phase I study with AFFITOPE® PD01A and PD03A to assess safety and tolerability as well as immunogenicity of this approach in MSA patients. Background:…PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach
Objective: To evaluate the safety and tolerability of epigallocatechin gallate (EGCG) in high doses and its efficacy to slow down disease progression in patients with…Nilotinib for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of nilotinib on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Effects of mannitol treatment in a mice model of multiple system atrophy (MSA)
Objective: The aim of this study was to examine the effect of mannitol treatment in a mice model of MSA. Background: Alpha-synuclein aggregation represents the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- Next Page »